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Background: Osteoarthritis (OA) is a degenerative joint disease affecting approximately 27 million Americans, and
even more worldwide. OA is characterized by degeneration of subchondral bone and articular cartilage. In this
study, a chondrogenic fibrin/hyaluronic acid (HA)-based hydrogel seeded with bone marrow-derived mesenchymal
stem cells (BMSCs) was investigated as a method of regenerating these tissues for OA therapy. This chondrogenic
hydrogel system can be delivered in a minimally invasive manner through a small gauge needle, forming a
three-dimensional (3D) network structure in situ. However, an ongoing problem with fibrin/HA-based biomaterials is
poor mechanical strength. This was addressed by modifying HA with methacrylic anhydride (MA) (HA-MA), which
reinforces the fibrin gel, thereby improving mechanical properties. In this study, a range of fibrinogen (the fibrin
precursor) and HA-MA concentrations were explored to determine optimal conditions for increased mechanical
strength, BMSC proliferation, and chondrogenesis potential in vitro.
Results: Increased mechanical strength was achieved by HA-MA reinforcement within fibrin hydrogels, and was
directly correlated with increasing HA-MA concentration. Live/dead staining and metabolic assays confirmed that
the crosslinked fibrin/HA-MA hydrogels provided a suitable 3D environment for BMSC proliferation. Quantitative
polymerase chain reaction (qPCR) of BMSCs incubated in the fibrin/HA-MA hydrogel confirmed decreased
expression of collagen type 1 alpha 1 mRNA with an increase in Sox9 mRNA expression especially in the presence
of a platelet lysate, suggesting early chondrogenesis.
Conclusion: Fibrin/HA-MA hydrogel may be a suitable delivery method for BMSCs, inducing BMSC differentiation
into chondrocytes and potentially aiding in articular cartilage repair for OA therapy.
Keywords: Osteoarthritis, Fibrin, Hyaluronic acid, Mesenchymal stem cell, Hydrogel, Cartilage, Stem cell delivery,
Regenerative medicine, Tissue engineeringIntroduction
Over 30 million Americans suffer from arthritis and
other rheumatic (affecting joints and connective tissue)
conditions, and by 2030 nearly 25% of the American
population is expected to be affected by such conditions
[1]. Osteoarthritis (OA) represents the majority of these
cases, and is characterized by loss of articular cartilage
and subchondral bone. This condition causes severe
pain, and is the leading cause of chronic disability in the* Correspondence: daewon.park@ucdenver.edu
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unless otherwise stated.U.S. [1-3]. Articular cartilage damage in particular is dif-
ficult to treat due to the lack of nerves and vasculature
in the cartilage [4]. Some progress has been made in the
past two decades, and regeneration of injured or degen-
erated cartilage has been achieved using surgical tech-
niques such as debridement [5], microfracture [6-8],
mosaicplasty [9], perichondral grafting [10,11] and peri-
osteal grafting [12,13]. More recently, research has fo-
cused on the use of synthetic implants [14,15] for
cartilage regeneration. However, about 20% of synthetic
implants are known to fail approximately a decade after
implantation [16]. Furthermore, this method introduces
other surgery-associated risks due to the need for
surgical implantation [17]. The delivery of autologousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[22-25] for cartilage regeneration has shown some
promising results. MSCs in particular have received
much attention in cartilage regeneration, as they are
multipotent cells capable of differentiating into cartil-
age, bone, muscle, fat and marrow stroma in response
to appropriate signaling pathways [26]. However, be-
cause autologous chondrocytes and MSCs are highly
environment-sensitive, their use has been severely ham-
pered by the lack of suitable delivery methods [27]. For
example, unfavorable conditions of the delivery matrix
have led to autologous chondrocyte differentiation into
fibroblast-like cells, which form fibrous tissues that can
prevent healing [28].
Hyaluronic acid (HA) scaffolds have been well estab-
lished as a biomaterial [29] for MSC delivery. HA hydro-
gels have been used to induce MSC osteogenesis [30,31],
adipogenesis [32] and keratinogenesis [32] in vitro.
Chung et al reported that delivery of MSCs in HA
hydrogels promoted chondrogenic gene expression [33].
HA is known to directly interact with the fibrin precur-
sor fibrinogen through reversible complex ionic interac-
tions [34], yet it provides a sufficiently non-adhesive
surface that allows cells to move more freely [35]. Fibrin
scaffolds have also been investigated for MSC delivery
both in vitro [23,24] and in vivo [24,36-38]. A recent
study concluded that a system comprising bone marrow-
derived MSCs (BMSCs) embedded within fibrin gels with
TGFβ3 was able to stimulate appropriate differentiation
and articular cartilage regeneration both in vitro and
in vivo [23,39].
In general, these chondrogenic hydrogels should be
biocompatible, possess sufficient mechanical strength,
allow good adhesion of MSCs, and permit diffusion of
nutrients and differentiation factors to induce chondro-
genesis and hence cartilage repair [40]. Pure unmodified
fibrin hydrogels possess excellent biocompatibility since
they contain native arginine-glycine-aspartic acid (RGD)
sites for MSC attachment [41]; however, without rein-
forcements or crosslinking, they possess low mechanical
strength [42-45]. Although HA hydrogels possess better
mechanical strength, they lack adhesive motifs [31] and
thus deter cell proliferation at higher concentrations
(>1 mg/mL) [30,46].
In this study, to exploit the advantages of both fibrin
and HA, we fabricated a fibrin gel reinforced by cross-
linked hyaluronic acid methacrylate (HA-MA). This
fibrin/HA-MA hydrogel was examined to determine its
in vitro mechanical and biological properties, and chon-
drogenesis was examined by BMSCs in the hydrogel. We
hypothesized that the combination of fibrin and HA-
MA would promote cell attachment and proliferation,
and subsequently induce chondrogenesis, and thus car-
tilage regeneration and repair.Results and discussion
BMSC phenotype verification
Phenotypical surface protein expression of BMSCs was
confirmed by flow cytometry (Figure 1) after incubating
BMSCs with the antibodies unlabeled with fluorescent
dyes (Figure 1A, B and C), anti-CD34 antibody (Figure 1D,
E and F) and fluorescent-labeled antibodies, CD105-PE,
CD73-PerCP, CD-90APC, CD44-FITC & CD34-FITC
(Figure 1G, H and I). The first graph of each case
(Figure 1A, D and G) is the side scatter channel (SSC)
vs. forward scatter channel (FSC). SSC is a measure of
cell granularity, while FSC represents overall cell size.
The next two graphs of each case represent the fluores-
cent intensity through channels FL1 (fluorescein isothio-
cyanate, FITC) and FL2 (phycoerythrin, PE) (Figure 1B, E
and H), and FL3 (peridinin chlorophyll protein complex,
PerCP) and FL4 (allophycocyanin, APC) (Figure 1C, F
and I). Based on the fluorescent tag of the antibodies,
positive markers display a shift in their respective fluor-
escent channel. In the four-color graphs (Figure 1G, H
and I), there is a shift to the upper right quadrant of
both fluorescence graphs, which signifies a positive re-
sult for all four markers. All markers were run individu-
ally with positive results. The unlabeled cell population
was used to determine the placement of the quadrants.
Thus, the BMSCs were verified to possess the typical
phenotype necessary for them to undergo chondrogenesis.
HA-MA characterization
The successful conjugation of MA to HA was confirmed
by proton nuclear magnetic resonance (1H NMR) spectra
(Figure 2). The NMR spectrum of native HA (Figure 2A)
confirmed the presence of HA methyl protons at 1.9 ppm
[29]. After conversion, the protons in methacrylate vinyl
groups appeared at 5.6 ppm and 6.1 ppm, and the MA
methyl protons were confirmed at 1.8 ppm (Figure 2B).
Degree of methacrylation was determined, as described
previously [47], by the ratio of the integral of the HA me-
thyl proton peak (at ~1.9 ppm) to that of the protons of
MA (at ~5.6 ppm and ~6 ppm). The degree of methacry-
lation was calculated as 95 ± 13%, which represents almost
one methacrylate group per disaccharide unit of HA.
BMSC viability & proliferation
BMSC activity was examined using a metabolic assay after
2, 4, and 6-day culture in different fibrin/HA-MA hydro-
gel formulations (Figure 3). No significant statistical dif-
ferences between 4 mg/mL (Figure 3A) and 6 mg/mL
(Figure 3B) fibrinogen groups were observed. However,
the HA-MA concentration in each group influenced
cellular activity. Within the two groups, there was sig-
nificant statistical difference (p < 0.05) as calculated by
one-way ANOVA. We, further, calculated the p values
between individual group-pairs by student’s t-Test. With
Figure 1 Flow cytometry verifies BMSC phenotype via positive and negative surface markers. Unlabeled BMSCs: (A) FSC vs. SSC and (B-C)
Absence of fluorescence detected through any channels. BMSCs treated with CD34-FITC indicate no CD34 expression: (D) FSC vs. SSC, (E) all cells
were FITC-negative as detected through channels FL1 and FL2 (100.0% in Q1-LL) and (F) through channels FL3 and FL4 (100.0% in Q2-LL).
BMSCs treated with CD105-PE, CD73-PerCP, CD90-APC, CD44-FITC indicate expression of all four surface proteins: (G) FSC vs. SSC, (H) 99.8% of
cells (Q1-UR) were PE, PerCP, APC and FITC-positive as detected through FL1 and FL2 and (I) 99.6% of cells (Q2-UR) were detected positive
through FL3 and FL4.
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4 mg/mL and 6 mg/mL fibrinogen concentrations sup-
ported substantial cell activity with HA-MA concentra-
tions below 1 mg/mL. Gel compaction occurred due to
the stresses imposed by the BMSC contraction in the gel
matrix [48]. Gel compaction could have been increased
due to the presence of TGFβ [49,50]. Based on preliminaryobservations (data not shown), fibrinogen concentrations
less than 3 mg/mL resulted in gel compaction after only
two days in culture, after which cells migrated from inside
the gel to the bare plate. This suggests that the hydrogels
with fibrinogen concentrations below 3 mg/mL may be
mechanically unreliable. 6 mg/mL was selected as the
upper limit due to the fact that higher concentrations
Figure 2 1H NMR spectra of HA (A) and HA-MA (B) with proton peaks in the methyl groups as well as the sugar rings labeled. 1H for
relevant peaks in each figure have been underlined.
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tion. The BMSC viability was also visualized by live/dead
staining (Figure 4), which showed increasing numbers of
viable cells and cell density at successive time points for
both 4 mg/mL and 6 mg/mL fibrinogen concentrations. It
was evident that there were a greater number of cells out-
lined in day 6 compared to day 2 in both the 4 mg/mL and
6 mg/mL conditions. The use of both the metabolic assay
and live/dead staining is a strong indication of cellular pro-
liferation. Metabolic activity alone is not reliable enough
to ensure cell division; however, the quantitative meas-
ure of cellular activity with the increase in cell density
as determined by live/dead staining strongly suggests
cellular proliferation. A decrease in cellular proliferation
as a function of mechanical strength has been recently
shown in similar hydrogels. Fibrin constructs containing
HA modified with tyramine capable of crosslinking in
the presence of hydrogen peroxide revealed a decrease
in proliferation of endothelial cells with increased
mechanical strength [51].Mechanical and structural characterization of
fibrin/HA-MA hydrogels
To examine mechanical stiffness of the fibrin/HA-MA
hydrogels, unconfined compression tests were performed
to determine the compressive modulus at 20% strain
(Figure 5), as described previously [47]. One-way ANOVA
comparison of the data confirmed that the groups were
statistically different (p < 0.05). Student’s t-Test was used
to find the p value between two groups to determine any
statistically significant difference (p < 0.05). Allowing HA-
MA concentrations to vary from 0 to 1.5 mg/mL, the
compressive modulus of the fibrin/HA-MA hydrogel
with 4 mg/mL fibrinogen varied from 1.62 ± 0.6kPa to
4.19 ± 0.28kPa, and the compressive modulus of the fi-
brin/HA-MA hydrogel with 6 mg/mL fibrinogen varied
from 3.39 ± 0.91kPa to 6.76 ± 0.52kPa. Since there was
no statistically significant difference between the two
conditions 4 mg/mL of fibrinogen with 0 mg/mL of
HA-MA and 4 mg/mL of fibrinogen with 0.5 mg/mL of
HA-MA (p = 0.1916), we decided to ignore the small
Figure 3 BMSC metabolic activity in fibrin/HA-MA hydrogels
with varying HA-MA concentrations. (A) 4 mg/mL and (B) 6 mg/mL
fibrinogen. * – Statistically significant difference between successive
days for a given HA-MA concentration (p < 0.05). † – Statistically
significant difference between successive HA-MA concentrations for
a given day (p < 0.05).
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6 mg/mL fibrinogen hydrogel possessed the higher com-
pressive modulus at each HA-MA concentration. Increas-
ing concentrations of both fibrinogen and HA-MA was
directly correlated to an increased compressive modulus.
Reinforcement with HA-MA crosslinking marginally im-
proved mechanical strength over previously demonstrated
pure fibrin hydrogels [42-45]. Since the gel was not stable
below 3 mg/mL concentration, we could not measure the
compressive strength at the lower concentrations.
Fibrinogen (fibrin-precursor) and HA-MA form a gel
with an interpenetrating network of fibers through ionic
and chemical interactions [34,51,52]. The hydrogel was
then reinforced using UV photocrosslinking, which was
achieved by photocrosslinking through the polymerizable
vinyl group (–C =C–) present on the methacrylate side
chain. The fibrin/HA-MA hydrogel even after crosslinking
would still be completely biodegradable since the degrad-
ation of the hydrogel could be achieved through thehydrolysis of the ester bond present in the methacrylate
side chain and the ether group present in the main hyalur-
onic acid backbone. To gain further insight into the struc-
ture of the hydrogels, field emission scanning electron
microscopy (FESEM) was performed (Figure 6). The fibrin
gels without HA-MA (Figures 6A and B) showed fibrous
structure with pore sizes on the order of 1 μm. Addition
of HA-MA resulted in a more sheet-like morphology with
pore sizes in the range of 10-100 μm (Figure 6C). Magni-
fying further into the fibrin/HA-MA construct showed
that fibrin fibers were still embedded within the structure
(Figure 6D), indicating that the gelation occurred as
intended by design: formation of fibrin gel followed by
HA-MA reinforcement and crosslinking. Since 6 mg/mL
fibrinogen with 1 mg/mL HA-MA led to well-controlled
proliferation and an increase in mechanical strength, this
fibrin/HA-MA hydrogel formulation was used for further
study in vitro to determine mRNA expression of key
chondrogenic markers.
mRNA Expression analysis
To determine chondrogenic potential, the cells were in-
cubated within as-selected hydrogel for 12 days, and, the
gene expression of collagen type 1 alpha 1 (COL1A1),
collagen type 2 alpha 1 (COL2A1), SOX9 and aggrecan
(ACAN) was assayed using qPCR (Figure 7). A platelet
lysate (PL) was used as a supplementation to mimic real-
life applications using BMSCs, since it is known to contain
the growth factors such as transforming growth factor
(TGFβ) that promote chondrogenesis [25]. While latent
TGFβ was not quantified, active TGFβ concentration was
quantified at 8.97 ng/mL using the Quantikine ELISA kit
and other researchers have reported supplementation in
the range of 5-20 ng/mL [53,54]. In the compared data
set, one-way ANOVA confirmed that the data was statisti-
cally different (p < 0.05). The fold increase of mRNA tran-
scripts was normalized to cells within fibrin/HA-MA gels
supplemented with 10% fetal bovine serum (FBS). There
was a downregulation of COL1A1 in all conditions with a
significant downregulation in BMSCs in the fibrin/HA-
MA containing PL (Figure 7A). SOX9 upregulation was
observed for all conditions with a statistically significant
difference in the fibrin/HA-MA with PL (Figure 7B).
COL2A1 and ACAN genes were also upregulated in cer-
tain cases yet these genes were not expressed as strongly
as SOX9 or COL1A1 (Refer to Additional file 1: Figure
S1). A decrease in COL1A1 expression and an increase in
SOX9 are good indicators of chondrogenesis [55]. Previ-
ous research has also indicated that the expressions of
SOX9 and COL1A1 are very strong in comparison to the
expression of COL2A1 and ACAN when BMSCs are cul-
tured in a fibrin-based or hyaluronic acid-based scaffold
[54,56-58]. Furthermore, SOX9 is by itself a favorable
marker that indicates the production of COL2A1 and
Figure 4 Representative images of live/dead staining of BMSCs in fibrin/HA-MA hydrogels. Live cells were stained with Calcein-AM (Red)
and dead cells with EthD-1 (Green). Formulation with 4 mg/mL fibrinogen with 0 mg/mL HA-MA at (A) day 2, (B) day 4, and (C) day 6.
Formulation with 4 mg/mL fibrinogen with 1 mg/mL HA-MA at (D) day 2, (E) day 4, and (F) day 6. Formulation with 6 mg/mL fibrinogen with 1
mg/mL HA-MA at (G) day 2, (H) day 4, and (I) day 6. Scale bar: 100 μm.
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lular components during chondrogenesis in vivo [59].
Conclusion
The use of a composite hydrogel formulated with 6 mg/
mL fibrinogen and 1 mg/mL HA-MA promoted optimalFigure 5 Compressive modulus of fibrin/HA-MA hydrogels at
20% strain. *Statistically significant difference between successive
HA-MA concentrations for a given fibrinogen concentration
(p < 0.05). † – Statistically significant difference between different
fibrinogen concentrations for a given HA-MA concentration (p < 0.05).BMSC proliferation. Crosslinking reinforcement of the
fibrin scaffold with HA-MA improved the compressive
modulus of fibrin/HA-MA hydrogel. Increased expres-
sion of Sox9 and decreased expression of type I collagen
demonstrated the chondrogenic potential of the fibrin/
HA-MA composite hydrogel, and the fibrin/HA-MA
system may indeed be a promising cell delivery vehicle
capable of localizing BMSCs to the site of cartilage
injury and promoting chondrogenesis.
Materials and methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM), phosphate
buffered saline (PBS), trypsin and alpha minimum essen-
tial media (AMEM) were obtained from Gibco Life Tech-
nologies (Grand Island, NY). Fetal bovine serum (FBS)
was purchased from Atlas Biologicals (Fort Collins, CO),
and doxycycline was purchased from APP Pharmaceutical
(Schaumburg, IL). The antibodies CD105-Phycoerythrin
(CD105-PE), CD73-Peridinin chlorophyll protein com-
plex (CD73-PerCP), CD90-Allophycocyanin (CD-90A
PC), CD44-Fluorescein isothiocyanate (CD44-FITC)
and CD34-FITC were purchased from BD Biosciences
(Franklin Lakes, NJ). Bovine serum albumin (BSA), meth-
acrylic anhydride (MA), hyaluronic acid (HA) sodium salt
from Streptococcus equi, sodium hydroxide, fibrinogen
from human plasma (50-70% protein, >80% clottable),
Figure 6 Scanning electron micrographs of (A) 6 mg/mL fibrinogen with no HA-MA at 5000×, (B) 6 mg/mL fibrinogen with no HA-MA
at 10,000×, (C) 6 mg/mL fibrinogen with 1 mg/mL HA-MA at 200x, and (D) 6 mg/mL fibrinogen with 1 mg/mL HA-MA at 5000×. Scale
bar: 1 μm.
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(800-1200 IU/mL) and ethanol (>99.5%) were obtained
from Sigma Aldrich (St. Louis, MO). Dialysis membrane
(MWCO 3500 Da) was purchased from VWR Inter-
national (Denver, CO). For the cell live/dead assay, Cell-
Trace™ Calcein Red-Orange, Sytox® Green and resazurin
(PrestoBlue®) were purchased from Molecular Probes
(Eugene, OR). The RealTime Ready Cell Lysis Kit, RNA
Master Hydrolysis Probes kit, probes for aggrecan
(ACAN), SOX9, collagen type 2 alpha 1 (COL2A1) and
collagen type I alpha 1 (COL1A1) and left and right
primers and the LightCycler II 480 polymerase chain
reaction (PCR) platform were obtained from Integrated
DNA Technologies (Coralville, IA). The Quantikine
ELISA kit for quantifying TGFβ was obtained from
R&D Systems (Minneapolis, MN).
Equipment
Flow cytometry was performed on an Accuri C6 Flow
Cytometer (BD Biosciences). Imaging for the live/dead
assay was performed on a fluorescent microscope (AMG
EVOS FL, Advanced Microscopy Group). To quantify
cell growth, a Fluoroskan Ascent FL 2.5 fluorescent
micro-plate reader with excitation/emission filters 544/
590 (Thermo Scientific) was used. Hydrogel samples
were uniaxially compressed on an Insight mechanical
tensile system (MTS Systems). Proton nuclear magnetic
resonance (1H NMR) spectroscopy was performed on a
Varian INOVA 500 MHz spectrometer (International
Equipment Trading Ltd.) with 5 mm triple resonance1H/13C/15 N probe and sensitivity of 850:1. For field
emission scanning electron microscopy (FESEM), the sam-
ples were sputter-coated with gold in a Cressington 108
Auto Sputter Coater (Cressington Scientific Instruments)
and imaged under a JEOL JSM-7401 F field emission scan-
ning electron microscope (JEOL USA Inc.). A LightCycler
II 480 PCR platform (Integrated DNA Technologies) was
used to analyze mRNA expression profiles.
BMSC isolation and culture
Age, sex and number of donors are not disclosed since it
is not a non-human subject research as determined by
Colorado Multiple Institutional Review Board. This infor-
mation was not available to us to ensure these donors can-
not be traced. However, all donors undergoing a bone
marrow nucleated cell procedure consented to providing
bone marrow for research purposes. Bone marrow was
fractionated by centrifugation and the buffy coat layer was
isolated and plated at a cell seeding density of 1×106 cells/
cm2 in tissue culture flasks with DMEM supplemented
with 10% FBS and 5 μg/mL doxycycline. Cells were incu-
bated under 5% CO2 and 5% O2 at 37°C. Media was chan-
ged every two days, washing twice with PBS before adding
fresh media. Between days 6 and 10, colony formation was
assessed and cells were harvested using trypsin. Cells were
counted and re-plated at 6000 cells/cm2 in AMEM with
10% FBS and 5 μg/mL doxycycline. Flasks were trans-
ferred to normoxic conditions with 21% O2 and 5% CO2
at 37°C. Media was changed every two days until cells
were approximately 80% confluent.
Figure 7 mRNA expression for BMSCs. (A) collagen type 1 alpha
1 gene and (B) SOX9 gene. All data has been normalized to fibrin/
HA-MA with 10% FBS condition. Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) is the housekeeping gene. * – Statistical
significance from the fibrin/HA-MA with 10% FBS condition
(p < 0.05) and † – Statistical significance from the Fibrin with PL
condition (p < 0.05).
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The human BMSC phenotype was verified in accordance
with the Mesenchymal and Tissue Stem Cell Committee
of the International Society for Cellular Therapy criteria:
the surface protein expression must be positive for
CD105, CD73 and CD90 and negative for at least one of
the following: CD45, CD34, CD14 or CD11b [60]. CD44
has also been documented as a phenotypical MSC marker
[61-63] and was also assayed for. CD105-PE, CD73-PerCP,
CD90-APC, CD44-FITC and CD34-FITC surface markers
were assessed using an Accuri C6 Flow Cytometer. Ap-
proximately 50,000 cells per surface protein, plus another
50,000 for four-color analysis, were centrifuged to a pellet
and washed in PBS containing 2% BSA. The antibody
surface markers (CD105-PE, CD73-PerCP, CD90-APC,
CD44-FITC and CD34-FITC), at a concentration of 5 μg/
mL, were added with cells and incubated in 2% BSA/PBSsolution for 1 hour. Unbound antibody was removed; the
cells were re-suspended in PBS to be run through the flow
cytometer, gated at 10,000 events. An unlabeled popula-
tion was run as a control to determine gating for the
detection of positive and negative shifts in fluorescence;
gating remained constant for all runs.
Modification of HA
The modification of HA was performed as described
previously [40]. Briefly, HA sodium salt from Strepto-
coccus equi (MW 1.5-1.8 MDa) was suspended to a final
1% (w/v) solution in diH2O. The solution was placed in
a round bottom flask and cooled to 5°C in a water bath
with stirring. A 10 molar excess of MA was added to the
flask and the solution was maintained at pH 10 using
5 N NaOH. After 24 hours, the reaction mixture was
slowly added to excess ethanol for precipitation. The
precipitate was centrifuged and the supernatant was dec-
anted. The ethanol precipitation was repeated once more
to further remove any unreacted MA. The HA-MA was
transferred to a round bottom flask to vacuum dry on a
rotary evaporator to remove excess ethanol. After dry-
ing, the sample was dissolved in diH2O and dialyzed for
three days against diH2O with refreshment of water every
day. The sample was then transferred to a 50 mL conical
tube and lyophilized under vacuum. The MA conversion
was determined using 1H NMR in D2O by the ratio of the
integral values between the MA proton peaks at 5.6 ppm
and 6.1 ppm to the methyl proton peak of HA at 1.9 ppm.
Fibrin/HA-MA hydrogel preparation with BMSCs
For BMSC culture, fibrinogen (final concentration: 4 mg/
mL or 6 mg/mL), aprotinin (30 KIU/mL), doxycycline
(5 μg/mL) and HA-MA (0.5, 1.0 or 1.5 mg/mL) were
mixed thoroughly in 200 μL AMEM with 1% (w/v)
photoinitiator (Irgacure 2959) and BMSCs (10,000 cells/
well) in 96-well plate. To form fibrin gel, thrombin was
added at 1 U/mL. Upon complete gelation, the gels were
exposed to UV light (10 mW/cm2) at, approximately,
350 nm for 5 minutes to crosslink HA-MA. The sam-
ples were limited to a 5-minute exposure to minimize
the negative effects of UV on the hydrogel. BMSCs were
cultured at 37°C under 5% CO2 using AMEM with 10%
FBS and 5 μg/mL doxycycline. Exposure to UV light
was limited to 5 minutes since it could have a negative
effect on proteins and DNA within the cells.
BMSC viability and proliferation
BMSC viability and proliferation within fibrin/HA-MA
gels was investigated using live/dead staining and meta-
bolic activity assay at 2, 4 and 7 days. CellTrace™ Calcein
Red-Orange was added to a final concentration of 2 μM,
with respect to the total volume of gel and media, and
incubated for 15 minutes prior to observation. Similarly,
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2.5 μM and incubated for 5 minutes. After incubation,
BMSC viability was observed by fluorescence micros-
copy. To quantify cell growth, cultures were exposed to
PrestoBlue®. A 10-fold dilution of PrestoBlue® with respect
to the total gel and media volume was added to the media
and incubated for 2 hours on an orbital shaker. The media
was removed and transferred to a 96-well plate, and fluor-
escence was measured by microplate reader.
Mechanical testing
Hydrogels were prepared in 24-well plate to a final vol-
ume of 1 mL as described above without the addition of
BMSCs. PBS was added to allow the final gels to be fully
hydrated for 24 hours. Unconfined compression testing
with a 5 N load cell was performed using a 5kN MTS
Insight load frame material testing system. Compression
testing was performed at a 2 mm/min strain rate to 80%
strain. A stress-strain curve was plotted and an expo-
nential regression model was fitted to the data. The
modulus was calculated in the initial linear region at
20% strain.
Field emission scanning electron microscopy
Hydrogels were prepared as described above to a final
volume of 1 mL in 3 mL syringes with the tip removed.
Fibrin-only gels with a final concentration of 6 mg/mL
fibrinogen were compared to the same gels containing
1 mg/mL HA-MA. The samples were lyophilized until
dry and then cross-sectioned. The samples were placed
in a vacuum chamber to sputter-coat a thin layer of gold
evenly across the sample surface for 40s at an operating
current of 40 mA. The sample was then loaded into the
field emission scanning electron microscope for mor-
phological imaging. The sample was imaged under an
operating voltage of 5 kV.
mRNA expression analysis
To determine potential chondrogenesis, BMSCs were cul-
tured in 6 mg/mL fibrinogen gels with/without 1 mg/mL
HA-MA for 12 days with the supplementation of 10%




Collagen Type 1 Alpha 1 COL1A1
Collagen Type 2 Alpha 1 COL2A1
SRY-box containing gene 9 SOX9
† - Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) is the housekeeping geneplatelet rich fraction of human whole blood. PL was pre-
pared from the same blood draw and donor as to eliminate
discrepancies in growth factor concentrations between
conditions. Gels were harvested and washed with PBS, cen-
trifuged to a pellet and the supernatant decanted. The
probes for aggrecan (ACAN), SOX9, collagen type 2 alpha
1 (COL2A1) and collagen type 1 alpha 1 (COL1A1), and
left and right primers were mixed according to manufac-
turer’s instructions with template RNA from the samples.
Solutions were added to each well of a 96-well plate and
transferred to the LightCycler II 480 PCR platform. A one-
step reaction protocol was programmed into the machine
according to the manufacturer’s instructions. RealTime
ready Cell Lysis Kit contained a cell lysis solution and
RNase inhibitor that was added to each gel in volumes of
39.5 μL and 0.5 μL, respectively. This was incubated on ice
for 5 minutes and mixed thoroughly to extract mRNA
from cells within the gel. Two master mixes were prepared
before lysis, one containing primers and probes and the
other containing Tth deoxyribonucleic acid (DNA) poly-
merase (capable of RNA transcription), deoxyribonucleo-
tide triphosphates (dNTPs), an activator and an enhancer.
The primers and probes were mixed to final concentra-
tions of 5 μM probe and 5 μM total left and right primer.
Template, PCR grade water and both master mixes were
combined in ratios based on the manufacturer’s instruc-
tions yielding a final primer and probe concentration of
0.325 μM. Final reaction volume was 20 μL/well run in
triplicates for each probed mRNA. Glyceraldehyde-
3-Phosphate Dehydrogenase (GAPDH) was used as a
housekeeping gene with primers and probes provided
within the qPCR kit. The relative expression of each
mRNA was determined by comparing the critical thresh-
old values of the target genes, i.e. SOX9, COL2A1,
COL1A1 & ACAN, to that of the housekeeping gene,
GAPDH. Table 1 indicates the sequences of primers for
the various target genes. Fold expression of each condition
was determined by normalizing the relative expression of
the target sample with a reference sample of BMSCs
cultured in fibrin/HA-MA hydrogels substituted with 10%
FBS. Active TGFβ concentration was determined using
the Quantikine ELISA Kit.ogenesis
mRNA Sequence
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http://www.jbioleng.org/content/8/1/10Statistical analysis
All experiments were conducted with a sample size of
five unless otherwise noted with values reported as the
mean ± the standard deviation. One-way ANOVA was
used to calculate p-values to determine over all statis-
tical significance between all groups (p < 0.05). Unpaired
Student’s t-Tests were used to calculate p-values to
determine statistical significance (p < 0.05).
Additional file
Additional file 1: Figure S1. mRNA expression for BMSCs. (A) aggrecan
gene and (B) collagen type 2 alpha 1 gene. All data has been normalized
to fibrin/HA-MA with 10% FBS condition. Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) is the housekeeping gene. * – Statistical
significance from the Fibrin with 10% FBS condition (p < 0.05).
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